Prof. Dr. Michael Repka
Distinguished Professor, Department of Pharmaceutics and Drug Delivery, University of Mississippi, University, MS 38677, USA
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
26Years (2001-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications10 July 2015 in AAPS PharmSciTech
Journal Article
1 March 2017 in International Journal of Pharmaceutics
Journal Article
JZJIAXIANG ZHANG
JIAXIANG ZHANGXFXin Feng
Xin Feng
HPHemlata Patil
Hemlata Patil
RTRoshan V. Tiwari
Roshan V. Tiwari
Michael Repka1 January 2007 in Drug Development and Industrial Pharmacy
Journal Article
Michael RepkaSBSunil Kumar Battu
Sunil Kumar Battu
SUSampada B. Upadhye
Sampada B. Upadhye
STSridhar Thumma
Sridhar Thumma
MCMichael M. Crowley
Michael M. Crowley
JMJames W. McGinity
James W. McGinity
+2
The advent of high through-put screening in the drug discovery process has resulted in compounds with high lipophilicity and poor solubility. Increasing the solubility of such compounds poses a major challenge to formulation scientists. Various approaches have been adopted to address this including preparation of solid dispersions and solid solutions. Hot-melt extrusion is an efficient technology for producing solid molecular dispersions with considerable advantages over solvent-based processes such as spray drying and co-precipitation. Hot-melt extrusion has been demonstrated to provide sustained, modified, and targeted drug delivery. Improvements in bioavailability utilizing the hot-melt extrusion technique demonstrate the value of the technology as a potential drug delivery processing tool. The interest in hot-melt extrusion technology for pharmaceutical applications is evident from the increasing number of patents and publications in the scientific literature. Part II of this article reviews the myriad of hot-melt extrusion applications for pharmaceutical dosage forms including granules, pellets, tablets, implants, transmucosal, and transdermal systems.
1 January 2018 in International Journal of Pharmaceutics
Journal Article
Michael RepkaSBSuresh Bandari
Suresh Bandari
VKVenkata Raman Kallakunta
Venkata Raman Kallakunta
AVAnh Q. Vo
Anh Q. Vo
HMHaley McFall
Haley McFall
ABAjinkya M. Bhagurkar
Ajinkya M. Bhagurkar
+1
1 December 2008 in Expert Opinion on Drug Delivery
Journal Article
Michael RepkaSMSoumyajit Majumdar
Soumyajit Majumdar
SBSunil Kumar Battu
Sunil Kumar Battu
RSRamesh Srirangam
Ramesh Srirangam
SUSampada B Upadhye
Sampada B Upadhye
In today's pharmaceutical arena, it is estimated that more than 40% of new chemical entities produced during drug discovery efforts exhibit poor solubility characteristics. However, over the last d...
3 January 2023 in International Journal of Pharmaceutics: X
Journal Article
PLPreethi Lakkala
Preethi Lakkala
SMSiva Ram Munnangi
Siva Ram Munnangi
SBSuresh Bandari
Suresh Bandari
Michael RepkaThree-dimensional (3D) printing or Additive Manufacturing (AM) technology is an innovative tool with great potential and diverse applications in various fields. As 3D printing has been burgeoning in recent times, a tremendous transformation can be envisaged in medical care, especially the manufacturing procedures leading to personalized medicine. Stereolithography (SLA), a vat-photopolymerization technique, that uses a laser beam, is known for its ability to fabricate complex 3D structures ranging from micron-size needles to life-size organs, because of its high resolution, precision, accuracy, and speed. This review presents a glimpse of varied 3D printing techniques, mainly expounding SLA in terms of the materials used, the orientation of printing, and the working mechanisms. The previous works that focused on developing pharmaceutical dosage forms, drug-eluting devices, and tissue scaffolds are presented in this paper, followed by the challenges associated with SLA from an industrial and regulatory perspective. Due to its excellent advantages, this technology could transform the conventional "one dose fits all" concept to bring digitalized patient-centric medication into reality.
About Me
Dr. Michael A Repka received his B.S. in Pharmacy and Ph.D.
in Pharmaceutical Sciences with an emphasis in Pharmaceutics from the
University of Texas at Austin. In addition, he earned his D.D.S. from the
University of Texas Health Science Center at San Antonio. From a research
perspective, Dr. Repka has over 30 years of experience utilizing hot-melt
extrusion (HME) for pharmaceutical dosage forms and devices. Dr. Repka is a
Distinguished Professor in the Department of Pharmaceutics & Drug Delivery
(PDD) and Director of the Pii Center for Pharmaceutical Technology. He also
served as Chair of PDD for 17 years. Dr. Repka has been awarded >$8.9
million from grants and contracts, as PI or Co-PI, from NIH, Industry, other
Federal Agencies, and private support. The Department of Pharmaceutics &
Drug Delivery has over 60 graduate students and thus Dr. Repka has had the
opportunity to mentor, train and assist both M.S. and Ph.D. graduate students
in an enriched learning environment. Dr. Repka received the Distinguished Research and
Creative Achievement Award in 2020, which is the University’s highest research
honor, and was named a Fellow of the American Association of Pharmaceutical
Scientists in 2012. He serves as an editor for AAPS PharmSciTech and associate editor for the Journal of Drug Delivery Science and Technology, and he has served on the editorial advisory boards of nine respected pharmaceutical
journals.